Teva's Growth Story
This article was originally published in The Pink Sheet Daily
Executive Summary
A message to the market: We're big and getting bigger
You may also be interested in...
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.